Perspective Therapeutics is advancing the development of its radiopharmaceutical therapy [212Pb]VMT01 following promising data presented at the Society for Melanoma Research Congress. The therapy showed safety and efficacy in heavily pretreated patients, with no dose-limiting toxicities and prolonged progression-free survival. The trial is now testing a lower dose to optimize treatment in melanoma, both as a monotherapy and in combination with Nivolumab.